11/12/2024 | Press release | Distributed by Public on 11/12/2024 16:26
Delaware
|
68-0359556
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
|
501 Canal Blvd.
Richmond, California
|
94084
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Scott Willoughby
Senior Vice President and General Counsel
Sangamo Therapeutics, Inc.
501 Canal Blvd.
Richmond, California 94084
(510) 970-6000
|
Chadwick L. Mills
Courtney M.W. Tygesson
Cooley LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111
(415) 693-2000
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☒
|
|||
Non-accelerated filer
|
☐
|
Smaller reporting company
|
☒
|
|||
Emerging growth company
|
☐
|
|
• |
the Registrant's annual report on Form 10-K for the year ended December 31, 2023, which was filed with the Commission on March 13, 2024;
|
|
• |
the information specifically incorporated by reference into the Registrant's annual report on Form 10-K for the year ended December 31, 2023 from the Registrant's definitive proxy statement on Schedule 14A, which was filed with the Commission on April 19, 2024;
|
|
• |
the Registrant's quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024, which were filed with the Commission on May 9, 2024, August 6, 2024 and November 12, 2024, respectively;
|
|
• |
the Registrant's current reports on Form 8-K, which were filed with the Commission on January 19, 2024, February 6, 2024, March 25, 2024, April 30, 2024, June 5, 2024 and July 24, 2024; and
|
|
• |
the description of the Common Stock contained in the Registrant's registration statement on Form 8-A, which was filed with the Commission on March 31, 2000, including all amendments and reports filed for the purpose of updating such description, including Exhibit 4.1 of the Registrant's annual report on Form 10-K for the year ended December 31, 2023.
|
Item 8. |
Exhibits
|
Exhibit
Number
|
Description
|
|
Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.3 to the Registrant's Current Report on Form 8-K filed June 2, 2023).
|
||
Certificate of Amendment of the Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed June 5, 2024).
|
||
Fifth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed December 19, 2022).
|
||
5.1
|
Opinion of Cooley LLP.
|
|
23.1
|
Consent of Independent Registered Public Accounting Firm.
|
|
23.2
|
Consent of Cooley LLP is contained in Exhibit 5.1 to this Registration Statement.
|
|
24.1
|
Power of Attorney is contained on the signature page hereto.
|
|
Amended and Restated Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed June 5, 2024).
|
||
107
|
Filing fee table.
|
SANGAMO THERAPEUTICS, INC.
|
||
By:
|
/s/ Alexander D. Macrae
|
|
Alexander D. Macrae, M.B., Ch.B., Ph.D.
|
||
President and Chief Executive Officer
|
Signature | Ttle | Date | ||
/s/ Alexander D. Macrae
|
President, Chief Executive Officer and Director
|
November 12, 2024
|
||
Alexander D. Macrae, M.B., Ch.B., Ph.D.
|
(Principal Executive Officer)
|
|
||
|
|
|
||
/s/ Prathyusha Duraibabu
|
Senior Vice President and Chief Financial Officer |
November 12, 2024
|
||
Prathyusha Duraibabu
|
(Principal Financial and Accounting Officer)
|
|
||
|
|
|
||
/s/ H. Stewart Parker
|
Director and Chairman of the Board
|
November 12, 2024
|
||
H. Stewart Parker
|
|
|
||
|
|
|
||
/s/ Courtney Beers
|
Director |
November 12, 2024
|
||
Courtney Beers, Ph.D.
|
|
|
||
|
|
|
||
/s/ Robert F. Carey
|
Director |
November 12, 2024
|
||
Robert F. Carey
|
|
|
||
|
|
|
||
/s/ Kenneth J. Hillan
|
Director |
November 12, 2024
|
||
Kenneth J. Hillan, M.B., Ch.B.
|
|
|
||
|
|
|
||
/s/ Margaret A. Horn
|
Director |
November 12, 2024
|
||
Margaret A. Horn
|
|
|
||
|
|
|
||
/s/ John H. Markels
|
Director |
November 12, 2024
|
||
John H. Markels, Ph.D.
|
|
|
||
|
|
|
||
/s/ James R. Meyers
|
Director |
November 12, 2024
|
||
James R. Meyers
|
|
|
||
|
|
|
||
/s/ Karen L. Smith
|
Director |
November 12, 2024
|
||
Karen L. Smith, M.D., Ph.D., M.B.A., L.L.M.
|
|
|
||
|
|
|